Work

Abstract PS1-10-29: Complete tumor response during first-line endocrine therapy (ET) plus Cyclin Dependent Kinase 4/6 inhibitors (CDK4/6i) predicts excellent clinical outcomes in patients with Hormone Receptor-positive, Human Epidermal growth factor Receptor 2-negative advanced Breast Cancer (HR+/HER2- aBC)

Year: 2026
Type: conference-abstract
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7129430966
Cites:
Cited by:
Related to: